American Century Companies’s Sagimet Biosciences SGMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$588K Buy
76,095
+15,726
+26% +$107K ﹤0.01% 2550
2026
Q1
$315K Sell
60,369
-1,014
-2% -$5.65K ﹤0.01% 2629
2025
Q4
$363K Buy
61,383
+2,924
+5% +$21K ﹤0.01% 2592
2025
Q3
$401K Buy
58,459
+16,174
+38% +$131K ﹤0.01% 2565
2025
Q2
$322K Buy
42,285
+3,454
+9% +$14.6K ﹤0.01% 2646
2025
Q1
$127K Buy
38,831
+18,728
+93% +$78.6K ﹤0.01% 2812
2024
Q4
$90.5K Buy
+20,103
New +$102K ﹤0.01% 2845

Other funds holding SGMT

American Century Companies's SGMT Position: Q2 2026 in Review

American Century Companies increased its Sagimet Biosciences (SGMT) stake by 26% in Q2 2026, buying an estimated $107K and bringing the position to 76,095 shares worth $588K. The position accounts for ﹤0.01% of the portfolio, ranked #2550.

American Century Companies first reported a position in SGMT in Q4 2024 and has held it in 7 quarters since. 110 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • American Century Companies held 76,095 shares of Sagimet Biosciences worth $588K as of Q2 2026.
  • American Century Companies bought 15,726 Sagimet Biosciences shares in Q2 2026, an estimated $107K.
  • Sagimet Biosciences made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2550 holding.
  • American Century Companies first reported a position in Sagimet Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 110 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.